AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1-14 (Canceled).

15. (Currently Amended) A method for maintaining or improving the visual acuity and the field of vision in a patient in need of such treatment, said method comprising:

administering a drug comprising ~~an inhibitor of the enzyme that converts angiotensin I to angiotensin II~~ ramipril, wherein said drug maintains or improves visual acuity and the field of vision.

16. (Currently Amended) The method according to claim 15, wherein said ~~inhibitor of the enzyme that converts angiotensin I to angiotensin II~~ drug is an ophthalmic neuro-protector and/or a retinoprotector.

17. (Canceled) The method according to claim 15, wherein said inhibitor has:

an equilibrium inhibition constant K_i that governs the *in vitro* inhibition of rabbit converting enzyme by the inhibitor, wherein the constant is lower than that of enalaprilat (50 pmol/l); and

a constant k_4 for the reversible isomerization of the enzyme-inhibitor complex formed, wherein said constant k_4 is lower than that of the complex formed by enalaprilat and the converting enzyme (1.1×10^{-4}) in a medium of 50 mM/l Hepes, 300 mmol/l NaCl, 1 micromol/L $ZnCl_2$, pH 7.5.

18. (Canceled) The method according to claim 15, wherein vasodilatory activity of the inhibitor is present in the arteries and veins.

19. (Canceled) The method according to claim 15, wherein said drug comprising

said inhibitor is more lipophilic than enalaprilat.

20. (Canceled) The method according to claim 15, wherein said drug comprising said inhibitor is selected from the group of: ramipril, ramiprilat, a pharmaceutically acceptable salt of ramipril, a pharmaceutically acceptable salt of ramiprilat and derivatives thereof, wherein said derivatives can liberate ramiprilat into said patient.

21. (Currently Amended) The method according to claim 15, wherein said drug ~~comprising said inhibitor~~ is administered orally.

22. (Currently Amended) The method according to claim 21, wherein ~~said inhibitor in said drug~~ ramipril is administered at a dose of 0.5 to 5 mg/day.

23. (Currently Amended) The method according to claim 21, wherein ~~said inhibitor in said drug~~ ramipril is administered at a dose of 1 to 2 mg/day.

24. (Currently Amended) The method according to claim 21, wherein ~~said inhibitor in said drug~~ ramipril is administered at a dose of 1.25 mg/day.

25. (Currently Amended) The method according to claim 15, wherein said drug ~~comprising said inhibitor~~ is administered parenterally.

26. (Currently Amended) The method according to claim 25, wherein said drug ~~comprising said inhibitor~~ is administered intravenously or intramuscularly or transdermically or topically.

27. (Currently Amended) The method according to claim 26, wherein said drug

~~comprising said inhibitor~~ is administered topically to the eye.

28. (Previously Presented) The method according to claim 27, wherein said drug is administered as an ophthalmic solution.

29. (Previously Presented) The method according to claim 15, wherein said patient has a degenerating chorioretinopathy or has an optic neuropathy or has both a degenerating chorioretinopathy and an optic neuropathy.

30. (Previously Presented) The method according to claim 15, wherein said patient has a glaucomatous neuropathy.

31. (Previously Presented) The method according to claim 15, wherein said patient has a degenerative chorioretinopathy in severe myopia.

32. (Previously Presented) The method according to claim 15, wherein said patient has age-related macular degeneration with or without sub-retinal neovessels.

33. (Previously Presented) The method according to claim 15, wherein said patient has a central serous chorioretinopathy or a chronic central serous chorioretinopathy.

34. (Previously Presented) The method according to claim 15, wherein said patient has a hereditary dystrophy of the retina.

35. (Previously Presented) The method according to claim 34, wherein said hereditary dystrophy of the retina is a retinitis pigmentosa.

36. (Previously Presented) The method according to claim 15, wherein said patient has a retinal venous occlusion.

37. (Previously Presented) The method according to claim 15, wherein said patient is aged.

38. (Canceled) A method for maintaining or improving the visual acuity and the field of vision in a patient in need of such treatment, said method comprising:

administering an ophthalmic drug comprising as an active ingredient ramipril or ramiprilat.